Calibra Medical gains further Finesse clearance
This article was originally published in Clinica
Executive Summary
The US FDA has granted 510(k) clearance for the Finesse insulin patch-pen for up to three-day use with Novo Nordisk's Novolog rapid-acting insulin. Developed by Calibra Medical, Finesse is a small, adhesively attached, flat device that can be operated through clothing to deliver bolus insulin doses. It has already gained FDA clearance for use with Eli Lilly's Humalog fast-acting insulin, and Calibra is pursuing further clearances for Finesse to deliver other manufacturers' insulin and diabetes drugs. It is also planning to develop next-generation models, including devices pre-filled with insulin.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.